MX2022014790A - Chimeric antigen receptors specific for p95her2 and uses thereof. - Google Patents
Chimeric antigen receptors specific for p95her2 and uses thereof.Info
- Publication number
- MX2022014790A MX2022014790A MX2022014790A MX2022014790A MX2022014790A MX 2022014790 A MX2022014790 A MX 2022014790A MX 2022014790 A MX2022014790 A MX 2022014790A MX 2022014790 A MX2022014790 A MX 2022014790A MX 2022014790 A MX2022014790 A MX 2022014790A
- Authority
- MX
- Mexico
- Prior art keywords
- p95her2
- chimeric antigen
- antigen
- antigen receptors
- relates
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
Abstract
The present invention relates to a chimeric antigen receptor (CAR) capable of targeting p95HER2-expressing cells. The invention also relates to a single-chain variable fragment (ScFv), to an antigen-binding domain and to an antibody or antibody fragment thereof capable of binding to the p95HER2 antigen. The invention also relates to a method of cancer diagnosis and to a pharmaceutical composition for use in a method of preventing or treating cancer comprising the CAR and/or the antigen-binding domain or the antibody of the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20382457.8A EP3915576A1 (en) | 2020-05-28 | 2020-05-28 | Chimeric antigen receptors specific for p95her2 and uses thereof |
PCT/EP2021/064383 WO2021239965A1 (en) | 2020-05-28 | 2021-05-28 | Chimeric antigen receptors specific for p95her2 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014790A true MX2022014790A (en) | 2023-04-03 |
Family
ID=70977904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014790A MX2022014790A (en) | 2020-05-28 | 2021-05-28 | Chimeric antigen receptors specific for p95her2 and uses thereof. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230348620A1 (en) |
EP (2) | EP3915576A1 (en) |
JP (1) | JP2023529082A (en) |
KR (1) | KR20230030591A (en) |
CN (1) | CN115776910A (en) |
AU (1) | AU2021279324A1 (en) |
BR (1) | BR112022024084A2 (en) |
CA (1) | CA3185329A1 (en) |
MX (1) | MX2022014790A (en) |
WO (1) | WO2021239965A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202114938D0 (en) * | 2021-10-19 | 2021-12-01 | Univ Oslo Hf | Her2 variant car |
WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
WO2023143322A1 (en) * | 2022-01-26 | 2023-08-03 | 山东先声生物制药有限公司 | P95her2 antibody and use thereof |
EP4253418A1 (en) | 2022-03-29 | 2023-10-04 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof |
EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
ATE207366T1 (en) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | IMMUNOCONJUGATES |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP1934174B1 (en) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
ES2342646B1 (en) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | METHOD OF DIAGNOSIS OF CANCERES THAT EXPRESS THE RECEIVER HER-2 OR ITS TRUNCATED VARIANTS. |
ES2527143T3 (en) | 2009-12-07 | 2015-01-20 | Fundació Privada Institució Catalana De Recerca I Estudis Avançants | Antibodies against truncated variant CTF-611 of HER2 |
EP3519437B1 (en) * | 2016-09-30 | 2021-09-08 | F. Hoffmann-La Roche AG | Bispecific antibodies against p95her2 |
EP3555620A1 (en) * | 2016-12-13 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Method to determine the presence of a target antigen in a tumor sample |
-
2020
- 2020-05-28 EP EP20382457.8A patent/EP3915576A1/en not_active Withdrawn
-
2021
- 2021-05-28 US US17/999,769 patent/US20230348620A1/en active Pending
- 2021-05-28 EP EP21729863.7A patent/EP4157336A1/en active Pending
- 2021-05-28 BR BR112022024084A patent/BR112022024084A2/en not_active Application Discontinuation
- 2021-05-28 WO PCT/EP2021/064383 patent/WO2021239965A1/en active Application Filing
- 2021-05-28 KR KR1020227045910A patent/KR20230030591A/en unknown
- 2021-05-28 CA CA3185329A patent/CA3185329A1/en active Pending
- 2021-05-28 AU AU2021279324A patent/AU2021279324A1/en active Pending
- 2021-05-28 JP JP2022573273A patent/JP2023529082A/en active Pending
- 2021-05-28 CN CN202180049697.XA patent/CN115776910A/en active Pending
- 2021-05-28 MX MX2022014790A patent/MX2022014790A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115776910A (en) | 2023-03-10 |
WO2021239965A1 (en) | 2021-12-02 |
EP3915576A1 (en) | 2021-12-01 |
KR20230030591A (en) | 2023-03-06 |
EP4157336A1 (en) | 2023-04-05 |
US20230348620A1 (en) | 2023-11-02 |
JP2023529082A (en) | 2023-07-07 |
AU2021279324A1 (en) | 2022-12-22 |
CA3185329A1 (en) | 2021-12-02 |
BR112022024084A2 (en) | 2023-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014790A (en) | Chimeric antigen receptors specific for p95her2 and uses thereof. | |
JP2019535670A5 (en) | ||
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
MX2021005708A (en) | Anti-nkg2a antibodies and uses thereof. | |
PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
MX2020012567A (en) | Anti-ox40 antibodies and methods of use. | |
JOP20180042A1 (en) | Humanized Antigen-Binding Domains and Methods of Use | |
JP2018512379A5 (en) | ||
BR112014018481A2 (en) | monoclonal or polyclonal antibody or antigen-binding fragment thereof, polynucleotide, monoclonal antibody, vector, hybridoma, antibody, hybridoma 5166-2 and / or 5166-9, antigen-binding antibody or fragment, pharmaceutical composition, antibody use or antibody binding fragment, method for treating cancer, method for diagnosing cancer in an individual, antibody, method, composition or use | |
RU2018124319A (en) | NEW ANTIBODIES TO CLAUDIN AND WAYS OF THEIR APPLICATION | |
AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
MX2022011951A (en) | Antibodies binding siglec15 and uses thereof. | |
MX2021011750A (en) | Anti-egfrviii antibodies and antigen-binding fragments thereof. | |
PE20230839A1 (en) | LAIR-1 BINDING AGENTS AND METHODS FOR THEIR USE | |
MX2022007353A (en) | Novel ddr1 antibodies and uses thereof. | |
MX2021010116A (en) | Anti-pd-l1 antibody and use thereof. | |
MX2021003168A (en) | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use. | |
ZA202206438B (en) | Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof | |
MX2023004275A (en) | Anti-pd-1/cd40 bispecific antibodies and uses thereof. | |
MX2023013726A (en) | Anti-cea and anti-cd137 multispecific antibodies and methods of use. | |
MX2022008421A (en) | Anti-galectin-9 antibody and uses thereof. | |
MX2022005949A (en) | Anti-ror-2 antibodies and methods of use. | |
MX2021008760A (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof. | |
MX2022002363A (en) | Chimeric antigen receptor system and uses thereof. | |
MX2022006728A (en) | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies. |